Cytosorbents Corp. CTSO
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Cytosorbents Corp. (CTSO) Business Model and Operations Summary
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Key Insights
Cytosorbents Corp. (CTSO) Core Market Data and Business Metrics
Latest Closing Price
$1Market Cap
$63.59 MillionAverage Daily Trade Volume
245,976 SharesPrice-Earnings Ratio
-2.78Total Outstanding Shares
54.83 Million SharesCEO
Dr. Phillip P. Chan M.D., Ph.D.Total Employees
186Dividend
No dividendIPO Date
May 17, 2005SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
NASDAQHeadquarters
305 College Road East, Princeton, NJ, 08540
Historical Stock Splits
If you bought 145 shares of CTSO before June 28, 2006, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| December 5, 2014 | 1-for-25 (Reverse Split) |
| June 28, 2006 | 1-for-5.8 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-18.49 Million |
| Net Cash Flow, Continuing | $2.20 Million |
| Net Cash Flow From Financing Activities | $21.37 Million |
| Net Cash Flow | $2.20 Million |
| Net Cash Flow From Operating Activities | $-18.49 Million |
| Net Cash Flow From Investing Activities | $-681,159 |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Diluted Earnings Per Share | $-0.36 |
| Costs And Expenses | $59.98 Million |
| Revenues | $37.74 Million |
| Income/Loss From Continuing Operations Before Tax | $-4.17 Million |
| Operating Income/Loss | $-22.15 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-18.67 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-13.52 Million |
| Comprehensive Income/Loss Attributable To Parent | $-19.36 Million |
| Comprehensive Income/Loss | $-19.36 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Noncurrent Liabilities | $26.37 Million |
| Other Non-current Liabilities | $12.57 Million |
| Accounts Payable | $2.34 Million |
| Other Non-current Assets | $21.94 Million |
| Inventory | $3.25 Million |
| Assets | $47.80 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||